<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01620268</url>
  </required_header>
  <id_info>
    <org_study_id>CK2012-001</org_study_id>
    <nct_id>NCT01620268</nct_id>
  </id_info>
  <brief_title>An Open-Label, Study to Treat Patients With Renal Allograft and Polyoma BK Viruria</brief_title>
  <official_title>An Open-Label, Phase 2 Study to Treat Patients With Renal Allograft and Polyoma BK Viruria to Prevent Polyoma BK Viremia, Polyoma BK Nephropathy and Renal Allograft Rejection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Changzheng-Cinkate</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Changzheng-Cinkate</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the clinical efficacy and safety of a combination of leflunomide and&#xD;
      orotic acid in kidney transplant patients with high levels of Polyoma BK viruria for the&#xD;
      purpose of preventing Polyoma BK viremia and Nephropathy that could lead to kidney transplant&#xD;
      loss from viral damage, acute rejection or both.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, randomized trial that will evaluate the effect of a combination of&#xD;
      leflunomide and orotic acid for the treatment of Polyoma BK viruria. In this multicenter&#xD;
      trial, renal allograft patients with the diagnosis of Polyoma BK viruria as determined by a&#xD;
      viral level in the urine of 25 million or more copies/mL, and no detectable viremia, will&#xD;
      complete a screening visit (V1) to determine eligibility for the study based on&#xD;
      inclusion/exclusion criteria. Patients that meet the entrance criteria for this study will be&#xD;
      randomly assigned to one of two treatment groups at Visit (2) and enter a 4 month dosing&#xD;
      period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of recruitment&#xD;
  </why_stopped>
  <start_date type="Actual">July 2012</start_date>
  <completion_date type="Actual">June 2018</completion_date>
  <primary_completion_date type="Actual">June 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clearance of viruria</measure>
    <time_frame>12 weeks</time_frame>
    <description>Viral load of Polyoma BK virus in urine reduced from greater than or equal to 10 million copies/mL to less than 500,000 copies/mL or a 2 log reduction in copies/mL.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absence of viremia</measure>
    <time_frame>12 weeks</time_frame>
    <description>No more that 1000 copies of Polyoma BK Virus in the blood on two consecutive tests 2 weeks or more apart</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absence of Polyoma BK Nephropathy</measure>
    <time_frame>12 weeks</time_frame>
    <description>Absence of Polyoma BK Nephropathy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>No rejection of the renal allograft</measure>
    <time_frame>12 weeks</time_frame>
    <description>No rejection of the renal allograft</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Viruria</condition>
  <condition>Viremia</condition>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients receive standard of care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose adjusted leflunomide plus 600 mg orotic acid.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leflunomide and orotic acid</intervention_name>
    <description>Daily dose of leflunomide adjusted to target steady state blood levels of 50 ug/mL to 100 ug/mL of the active metabolite plus 600 mg orotic acid</description>
    <arm_group_label>Treatment Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients, 75 years of age or less, with the diagnosis of renal allograft Polyoma BK&#xD;
             viruria of 10 million or more copies/mL in their urine confirmed by PCR at the central&#xD;
             laboratory.&#xD;
&#xD;
          2. No viremia (viremia is defined as greater than 1,000 copies/ml plasma on two&#xD;
             consecutive tests two weeks or more apart as measured at the designated central&#xD;
             laboratory),&#xD;
&#xD;
          3. Serum creatinine &lt;2.0 mg/dL&#xD;
&#xD;
          4. Hct &gt; 30%&#xD;
&#xD;
          5. WBC &gt; 3,500 x 103/L&#xD;
&#xD;
          6. Platelet count &gt; 150,000 x 103/L&#xD;
&#xD;
          7. Normal values for ALT, AST and bilirubin; Alk Phos &lt; 2 X upper limits of normal&#xD;
&#xD;
          8. No symptomatic cardiac, pulmonary, GI, hepatic or neurologic disease&#xD;
&#xD;
          9. No other active infections&#xD;
&#xD;
         10. Receiving CyA or Tacrolimus, Mycophenolate/Azathioprine + prednisone.&#xD;
&#xD;
         11. Is not pregnant as verified by a pregnancy test&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Is not able to comply with study procedures and dosing.&#xD;
&#xD;
          2. Has psychiatric instability.&#xD;
&#xD;
          3. Has an active systemic infection including Hepatitis B or C, HIV, or on anti-viral&#xD;
             therapy within seven days of entering the study. Note however, that the subjects may&#xD;
             be taking ganciclovir, valaciclovir, acyclovir and valganciclovir and therefore these&#xD;
             are not exclusionary antiviral medications.&#xD;
&#xD;
          4. Has BK viremia (viremia is defined as greater than 1,000 copies/ml plasma on two&#xD;
             consecutive tests two weeks or more apart as measured at the designated central&#xD;
             laboratory), or has had a single episode of BK viremia. (viremia is defined as greater&#xD;
             than 1,000 copies/ml plasma on two consecutive tests two weeks or more apart as&#xD;
             measured at the designated central laboratory or the local laboratory),&#xD;
&#xD;
          5. Has a cancer diagnosis within past five years with potential for recurrence.&#xD;
&#xD;
          6. Has received experimental drug within past 3 months.&#xD;
&#xD;
          7. Is receiving immune suppressive drug other than those listed above calcineurin&#xD;
             inhibitor, mycophenolate/azathioprine and +/- corticosteroid)&#xD;
&#xD;
          8. Is a woman of child bearing potential or is a male with female partner of child&#xD;
             bearing potential who is unwilling to use reliable contraception.&#xD;
&#xD;
          9. Has any neurologic abnormalities including peripheral neuropathy.&#xD;
&#xD;
         10. Is receiving concomitant therapy with drug known to have hepatotoxic risk.&#xD;
&#xD;
         11. Has known or suspected liver disease or current alcohol abuse.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James W Williams, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cinkate Corp</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama, Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampa General Hospital</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush Univeristy</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Illinois, Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Chicago Transplant Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IU Health</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Lousiville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist University Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>June 13, 2012</study_first_submitted>
  <study_first_submitted_qc>June 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2012</study_first_posted>
  <last_update_submitted>December 3, 2018</last_update_submitted>
  <last_update_submitted_qc>December 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>leflunomide</keyword>
  <keyword>orotic acid</keyword>
  <keyword>Polyoma BK Viruria</keyword>
  <keyword>Polyoma BK Viremia</keyword>
  <keyword>Polyoma BK Nephropathy</keyword>
  <keyword>Renal Allograft Rejection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Viremia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leflunomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

